IL291240A - Variants of aav vector for ocular gene transfer - Google Patents
Variants of aav vector for ocular gene transferInfo
- Publication number
- IL291240A IL291240A IL291240A IL29124022A IL291240A IL 291240 A IL291240 A IL 291240A IL 291240 A IL291240 A IL 291240A IL 29124022 A IL29124022 A IL 29124022A IL 291240 A IL291240 A IL 291240A
- Authority
- IL
- Israel
- Prior art keywords
- gene delivery
- aav vector
- vector variants
- ocular gene
- ocular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206603 | 2019-10-31 | ||
| PCT/EP2020/080704 WO2021084133A1 (en) | 2019-10-31 | 2020-11-02 | Aav vector variants for ocular gene delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291240A true IL291240A (en) | 2022-05-01 |
Family
ID=68426130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291240A IL291240A (en) | 2019-10-31 | 2022-03-09 | Variants of aav vector for ocular gene transfer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12509705B2 (https=) |
| EP (1) | EP4051694B1 (https=) |
| JP (1) | JP7791546B2 (https=) |
| KR (1) | KR20220093163A (https=) |
| CN (1) | CN114729009A (https=) |
| AU (1) | AU2020373326A1 (https=) |
| CA (1) | CA3157464A1 (https=) |
| IL (1) | IL291240A (https=) |
| WO (1) | WO2021084133A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240252679A1 (en) * | 2021-05-28 | 2024-08-01 | Shanghai Regenelead Therapies Co., Ltd. | Recombinant adeno-associated virus having variant capsid, and application thereof |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| AU2023220219A1 (en) | 2022-02-17 | 2024-09-05 | Skyline Therapeutics Limited | Recombinant adeno-associated virus with modified aav capsid polypeptides |
| WO2024191778A1 (en) | 2023-03-10 | 2024-09-19 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| AU2024276934A1 (en) * | 2023-05-23 | 2025-12-18 | Innovec Biotherapeutics | Adeno-associated virus capsid protein, adeno-associated virus containing same, vector and use thereof |
| AU2024332181A1 (en) | 2023-08-31 | 2026-02-12 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2025051292A1 (zh) * | 2024-01-16 | 2025-03-13 | 广州译码基因科技有限公司 | 提高aav病毒对眼组织感染能力的衣壳蛋白突变体及其应用 |
| CN118459557B (zh) * | 2024-01-16 | 2024-11-22 | 沈阳兴齐眼药股份有限公司 | 提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用 |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2026033140A1 (en) * | 2024-08-09 | 2026-02-12 | Revvity Gene Delivery Gmbh | Variant aav capsid polypeptides targeting the eye |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| ES2308779T3 (es) | 1995-07-26 | 2008-12-01 | Astrazeneca Ab | Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas. |
| US20040248202A1 (en) | 1998-09-03 | 2004-12-09 | Wisconsin Alumni Research Foundation | Bacteriorhodopsin/G protein-coupled receptor chimeras |
| US9284363B2 (en) | 2006-07-26 | 2016-03-15 | Case Western Reserve University | System and method for controlling G-protein coupled receptor pathways |
| MY152003A (en) | 2008-05-29 | 2014-08-15 | Univ Leland Stanford Junior | Cell line, system and method for optical control of secondary messengers |
| WO2012051599A2 (en) | 2010-10-15 | 2012-04-19 | Eos Neuroscience, Inc. | Modulation neural pathways |
| CN105755044A (zh) * | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP3029063B1 (en) | 2011-06-24 | 2019-10-16 | Arctos Medical AG | Light-sensitive chimeric gpcr protein |
| CA2839938A1 (en) | 2011-06-28 | 2013-01-03 | University Of Rochester | Photoactivatable receptors and their uses |
| US20140087463A1 (en) | 2012-09-25 | 2014-03-27 | The Washington University | Optical control of cell signaling |
| EP3024497B1 (en) | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| BR112016017817A2 (pt) | 2014-02-06 | 2017-10-10 | Genzyme Corp | composições e métodos para o tratamento e a prevenção de degeneração macular |
| US20170007720A1 (en) | 2014-02-21 | 2017-01-12 | University Of Florida Research Foundation, Inc. | Methods and compositions for gene delivery to on bipolar cells |
| GB201403260D0 (en) | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
| EP4678754A3 (en) | 2014-03-11 | 2026-04-08 | Wayne State University | A modified mglur6 promoter and methods of use |
| AU2016219789B2 (en) | 2015-02-20 | 2021-03-25 | Fondazione Telethon | Methods and compositions for treating genetic eye diseases |
| US11021519B2 (en) * | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| US10533187B2 (en) | 2015-03-18 | 2020-01-14 | University Of Florida Research Foundation, Incorporated | Methods and compositions for restoration of cone function in BCM |
| CN105154470A (zh) | 2015-07-22 | 2015-12-16 | 华东师范大学 | 一种高效筛查g蛋白-偶联受体表达的融合基因构建方法 |
| US11364308B2 (en) * | 2016-05-13 | 2022-06-21 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and methods of use thereof |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| EP4653537A3 (en) | 2016-09-02 | 2026-01-07 | Keio University | Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function |
| US10376265B2 (en) | 2017-01-30 | 2019-08-13 | Ethicon Llc | Non-magnetic fragmentable tissue compression devices |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| US12043848B2 (en) * | 2017-10-16 | 2024-07-23 | Vigeneron Gmbh | AAV vectors |
| JP7029160B2 (ja) | 2017-11-24 | 2022-03-03 | 公立大学法人大阪 | 新規な光受容タンパク質 |
| CN111770999A (zh) * | 2017-11-27 | 2020-10-13 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和用于抑制血管生成的应用 |
| WO2020148913A1 (ja) | 2019-01-18 | 2020-07-23 | 俊英 栗原 | 網膜疾患の予防および進行抑制、視覚認知行動機能の改善、および視覚機能強化 |
| CN115052988A (zh) | 2019-11-18 | 2022-09-13 | 伯尔尼大学 | 用于眼部基因递送的给光型双极细胞特异性启动子 |
| US20240174743A1 (en) | 2019-11-29 | 2024-05-30 | Universität Bern | Chimeric opsin gpcr proteins |
-
2020
- 2020-11-02 CN CN202080074852.9A patent/CN114729009A/zh active Pending
- 2020-11-02 KR KR1020227018274A patent/KR20220093163A/ko not_active Ceased
- 2020-11-02 JP JP2022525579A patent/JP7791546B2/ja active Active
- 2020-11-02 US US17/755,434 patent/US12509705B2/en active Active
- 2020-11-02 CA CA3157464A patent/CA3157464A1/en active Pending
- 2020-11-02 WO PCT/EP2020/080704 patent/WO2021084133A1/en not_active Ceased
- 2020-11-02 AU AU2020373326A patent/AU2020373326A1/en not_active Abandoned
- 2020-11-02 EP EP20841660.2A patent/EP4051694B1/en active Active
-
2022
- 2022-03-09 IL IL291240A patent/IL291240A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4051694C0 (en) | 2025-07-02 |
| CN114729009A (zh) | 2022-07-08 |
| JP2023504773A (ja) | 2023-02-07 |
| CA3157464A1 (en) | 2021-05-06 |
| WO2021084133A1 (en) | 2021-05-06 |
| JP7791546B2 (ja) | 2025-12-24 |
| EP4051694B1 (en) | 2025-07-02 |
| US12509705B2 (en) | 2025-12-30 |
| EP4051694A1 (en) | 2022-09-07 |
| AU2020373326A1 (en) | 2022-06-02 |
| US20240287542A1 (en) | 2024-08-29 |
| KR20220093163A (ko) | 2022-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291240A (en) | Variants of aav vector for ocular gene transfer | |
| SG11202110789VA (en) | Gene therapy for eye pathologies | |
| IL287438A (en) | Variant aav capsids for intravitreal administration | |
| IL277667A (en) | Virus vectors for ocular tissues | |
| IL284742A (en) | AAV-mediated gene therapy restoring the autoperlin gene | |
| IL277270A (en) | Augmenting tissue-specific gene delivery through capsid modification | |
| GB201907302D0 (en) | Delivery system | |
| EP4013770A4 (en) | AAV CAPSID VARIANTS FOR GENE THERAPY | |
| PL3693325T3 (pl) | System dostawczy | |
| GB201905301D0 (en) | Gene therapy | |
| IL287956A (en) | Parthenogenesis garden | |
| IL279225A (en) | Cardiac AAV gene therapy for myocardial disease | |
| EP3634986A4 (en) | GENE THERAPY FOR EYE DISORDERS | |
| IL268946A (en) | Gene therapy for ocular disorders | |
| EP3765030A4 (en) | CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION | |
| IL292881A (en) | Bipolar cell-specific promoters for ocular gene delivery | |
| IL290944A (en) | A system for regulating gene expression | |
| EP4073087A4 (en) | Recombinant adeno-associated viral vector for gene delivery | |
| HK40079698A (en) | Aav vector variants for ocular gene delivery | |
| GB201916884D0 (en) | Nanoparticle-like delivery system | |
| EP3717024B8 (en) | Gene therapy for ocular improvement | |
| EP4043038A4 (en) | ARNSI EXPRESSION VECTOR | |
| HK40078512A (en) | On-bipolar cell-specific promoters for ocular gene delivery | |
| HK40065561A (en) | Variant aav capsids for intravitreal delivery | |
| HK40068650A (en) | Gene therapy for eye pathologies |